StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Capital expenditures by Year

Capital expenditures (Form 8-K Selected Cash Flow Information, $M) ($M)

QuarterlyAnnual

Gilead Sciences Capital expenditures: $563M in FY2025, up 7.6% from a year earlier.

Latest, FY2025
563
Period ended Dec 31, 2025
Change on a year earlier
+7.6%
523 in FY2024
History
6 years
Since FY2020
Sources
5
Documents cited below

Where the FY2025 figure comes from

“|| Purchases of property, plant and equipment | (205) | (147) | (563) | (523)”

Source: Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗

Reported in Form 8-K Selected Cash Flow Information.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCapital expenditures (Form 8-K Selected Cash Flow Information, $M) ($M)Year on yearSource
FY2025Dec 31, 2025563+7.6%Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
FY2024Dec 31, 2024523-10.6%Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
FY2023Dec 31, 2023585-19.6%Form 8-K (exhibit991earningspressrel.htm, filed 2025-02-11) ↗
FY2022Dec 31, 2022728+25.7%Form 8-K (exhibit991earningspressrel.htm, filed 2024-02-06) ↗
FY2021Dec 31, 2021579-10.9%Form 8-K (exhibit991earningspressrel.htm, filed 2023-02-02) ↗
FY2020Dec 31, 2020650–Form 8-K (exhibit991earningspressrel.htm, filed 2022-02-01) ↗

Cite this data

StockData. (2026). Gilead Sciences Capital expenditures ($M), annual FY2020–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rel-capex-row

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.